Nature Communications (Sep 2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- Olga Kondrashova,
- Monique Topp,
- Ksenija Nesic,
- Elizabeth Lieschke,
- Gwo-Yaw Ho,
- Maria I. Harrell,
- Giada V. Zapparoli,
- Alison Hadley,
- Robert Holian,
- Emma Boehm,
- Valerie Heong,
- Elaine Sanij,
- Richard B. Pearson,
- John J. Krais,
- Neil Johnson,
- Orla McNally,
- Sumitra Ananda,
- Kathryn Alsop,
- Karla J. Hutt,
- Scott H. Kaufmann,
- Kevin K. Lin,
- Thomas C. Harding,
- Nadia Traficante,
- Australian Ovarian Cancer Study (AOCS),
- Anna deFazio,
- Iain A. McNeish,
- David D. Bowtell,
- Elizabeth M. Swisher,
- Alexander Dobrovic,
- Matthew J. Wakefield,
- Clare L. Scott
Affiliations
- Olga Kondrashova
- The Walter and Eliza Hall Institute of Medical Research
- Monique Topp
- The Walter and Eliza Hall Institute of Medical Research
- Ksenija Nesic
- The Walter and Eliza Hall Institute of Medical Research
- Elizabeth Lieschke
- The Walter and Eliza Hall Institute of Medical Research
- Gwo-Yaw Ho
- The Walter and Eliza Hall Institute of Medical Research
- Maria I. Harrell
- Department of Obstetrics and Gynecology, University of Washington
- Giada V. Zapparoli
- Olivia Newton-John Cancer Research Institute
- Alison Hadley
- The Walter and Eliza Hall Institute of Medical Research
- Robert Holian
- The Walter and Eliza Hall Institute of Medical Research
- Emma Boehm
- The Walter and Eliza Hall Institute of Medical Research
- Valerie Heong
- The Walter and Eliza Hall Institute of Medical Research
- Elaine Sanij
- Research Division, Peter MacCallum Cancer Centre
- Richard B. Pearson
- Research Division, Peter MacCallum Cancer Centre
- John J. Krais
- Fox Chase Cancer Centre
- Neil Johnson
- Fox Chase Cancer Centre
- Orla McNally
- Royal Women’s Hospital
- Sumitra Ananda
- Royal Women’s Hospital
- Kathryn Alsop
- Research Division, Peter MacCallum Cancer Centre
- Karla J. Hutt
- Department of Medicine and Health Sciences, Monash University
- Scott H. Kaufmann
- Departments of Oncology and Molecular Pharmacology, Mayo Clinic
- Kevin K. Lin
- Clovis Oncology
- Thomas C. Harding
- Clovis Oncology
- Nadia Traficante
- Research Division, Peter MacCallum Cancer Centre
- Australian Ovarian Cancer Study (AOCS)
- Anna deFazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney Medical School, The University of Sydney and Department of Gynaecological Oncology, Westmead Hospital
- Iain A. McNeish
- Division of Cancer, Department of Surgery and Cancer, Imperial College London, Kensington
- David D. Bowtell
- Research Division, Peter MacCallum Cancer Centre
- Elizabeth M. Swisher
- Department of Obstetrics and Gynecology, University of Washington
- Alexander Dobrovic
- Olivia Newton-John Cancer Research Institute
- Matthew J. Wakefield
- The Walter and Eliza Hall Institute of Medical Research
- Clare L. Scott
- The Walter and Eliza Hall Institute of Medical Research
- DOI
- https://doi.org/10.1038/s41467-018-05564-z
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 16
Abstract
Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resistance in HGSOC.
